German biotech engineering T-cell receptor (TCR) bispecific drugs and cell therapies targeting cancer antigens like PRAME.
German biotech engineering T-cell receptor (TCR) bispecific drugs and cell therapies targeting cancer antigens like PRAME.
Has no approved product, so it lives on upfront and milestone payments from collaborations with large drug makers, plus share sales. Its main in-house programs target PRAME, a protein many tumours carry, while partners fund other candidates. Dutch-registered, with its research and operations based in Germany and the US.
Moat: narrow (IP / patents, process know-how). Proprietary TCR-discovery platform is licensed to multiple large pharma partners for milestones.
Headquarters: Tübingen, Germany · Founded: 2000 · Employees: 656
Size Immatics (IMTX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $913M, the 2286th largest of 3,085 United States companies the cockpit tracks. Shares closed at $6.10 on 18 Nov 2026.
Performance Over six months the shares fell 45.6%, against -20.9% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd lowest of 20 in its peer set.
Growth Revenue fell 44.5% over the last twelve months (peer median +2.4%); the operating margin is -588.5% (peer median 8.8%).
Valuation It trades at 8.5× enterprise value to sales against a peer median of 3.5× (3rd most expensive of 18).
Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $50.5M | $54.5M | $169M | $58.4M | $182M |
| Revenue growth | — | -68% | +189% | -68% | — |
| EBITDA | -$283M | -$197M | -$28.6M | -$103M | $38.8M |
| Net income | -$269M | -$222M | $16.5M | -$102M | $39.4M |
| Free cash flow | -$259M | -$207M | -$189M | -$13.6M | $99.2M |
| Capital expenditure | $3.97M | $7.68M | $17.8M | $33.5M | $6.53M |
| Total debt | $53.7M | $18.4M | $18.6M | $38.0M | $33.6M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Immatics IMTX | $913M | -46% | -44% | -589% | 8.5× | n/a |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | $1.44B | -7% | +13% | -7% | 2.3× | n/a |
| Iovance Biotherapeutics IOVA | $3.46B | +111% | +51% | -61% | 8.3× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | IMTX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -18.8% | -9.1% | 4th lowest of 21 |
| 6-month return | -45.6% | -20.9% | 3rd lowest of 20 |
| Distance from 52-week high | -50.9% | -46.6% | 8th lowest of 21 |
| Revenue growth (TTM) | -44.5% | +2.4% | 2nd lowest of 18 |
| Operating margin | -588.5% | 8.8% | 2nd lowest of 18 |
| EV / Sales | 8.5× | 3.5× | 3rd most expensive of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Immatics IMTX | United States | $913M | -46% | -44% | -589% | 8.5× | n/a | n/a |
| Genfleet Therapeutics (Shanghai) 2595.HK | Hong Kong | $912M | -42% | -55% | -457% | 55.9× | n/a | n/a |
| MoonLake Immunotherapeutics MLTX | United States | $918M | -37% | n/a | n/a | n/a | n/a | n/a |
| Lotus Pharmaceutical 1795.TW | Taiwan | $921M | -37% | +67% | 21% | 2.6× | -3.7% | +13.8% |
| Sichuan Huiyu Pharmaceutical 688553.SS | China | $904M | -28% | +14% | 7% | 3.5× | 19.4% | -6.0% |
| Zhejiang Garden Biopharmaceutical 300401.SZ | China | $922M | -14% | +2% | 24% | 5.2× | 9.1% | +13.4% |
| Oscotec 039200.KS | South Korea | $923M | -32% | +510% | 59% | 7.5× | -10.2% | +18.1% |
| Bio-Thera Solutions 688177.SS | China | $929M | -23% | +24% | -44% | 6.5× | n/a | n/a |
| Aktis Oncology AKTS | United States | $895M | -15% | +337% | -837% | 33.4× | n/a | n/a |
| Northeast Pharmaceutical 000597.SZ | China | $895M | -14% | -6% | 3% | 0.9× | -7.6% | -0.7% |
| Guangxi Wuzhou Zhongheng 600252.SS | China | $936M | -10% | -43% | -42% | 4.5× | 10.3% | -13.7% |
| KPC Pharmaceuticals 600422.SS | China | $940M | -6% | -41% | -10% | 1.8× | n/a | n/a |
| Harbin Gloria Pharmaceuticals 002437.SZ | China | $941M | -9% | -16% | 13% | 2.8× | 7.7% | -6.9% |
| Latigo Biotherapeutics LTGO | United States | $882M | n/a | n/a | n/a | n/a | n/a | n/a |
| Ningbo Menovo Pharmaceutical 603538.SS | China | $945M | -48% | +19% | 9% | 3.8× | 11.6% | +4.9% |
| Strides Pharma Science STAR.NS | India | $946M | -17% | +11% | 14% | 2.0× | 17.6% | +7.8% |
| SSY 2005.HK | Hong Kong | $948M | +8% | -4% | 12% | 2.2× | 2.3% | -0.5% |
| Sanofi Consumer Healthcare India SANOFICONR.NS | India | $869M | -26% | +23% | 36% | 8.3× | 17.7% | +22.7% |
| China Resources Boya Bio-pharmaceutical 300294.SZ | China | $959M | -21% | -27% | -19% | 2.5× | n/a | n/a |
| BeBetter Med 688759.SS | China | $960M | -58% | n/a | n/a | n/a | n/a | n/a |
| Pharming PHARM.AS | Netherlands | $867M | -6% | +2% | 9% | 2.2× | 2.4% | +12.4% |